Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Rang în acțiuni #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Preț acțiune
$3.12
Ultima sincronizare: 2026-09-01
Capitalizare de piață
$294.21M
Schimbare (1 zi)
-3.26%
Schimbare (1 an)
-54.86%
Țară
US
Tranzacționează Myriad Genetics, Inc. (MYGN)

Categorie

Prețul MYGN cu capitalizarea de piață a B
Myriad Genetics, Inc. Myriad Genetics, Inc.
MYGN
$3.12
Capitalizarea de piață a Myriad Genetics, Inc.(MYGN)
Capitalizare de piață: $294.21M
În anul September 2026, Myriad Genetics, Inc. are o capitalizare de piață de $294.21M. Acest lucru face ca Myriad Genetics, Inc. să fie a 16435th-a cea mai valoroasă companie din lume, conform datelor noastre. Capitalizarea bursieră reprezintă valoarea totală de piață a acțiunilor în circulație ale unei companii listate și este utilizată frecvent pentru a măsura valoarea unei companii.
Istoricul capitalizării de piață a Myriad Genetics, Inc. din 1995 până în 2026
MYGN în comparație cu top 5 cele mai populare stocks
Prețul pentru MYGN Activul B Capitalizarea de piață a B Rezultate
Myriad Genetics, Inc. Myriad Genetics, Inc.
$55,687.76 $294.21M
$5.260T +1,787,629.19%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$50,594.20 $294.21M
$4.779T +1,624,111.81%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$42,528.50 $294.21M
$4.017T +1,365,181.01%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$39,379.35 $294.21M
$3.719T +1,264,084.73%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$28,949.62 $294.21M
$2.734T +929,261.77%